FDA Grants Bimeda's Bimectin EUA for New World Screwworm Prevention in Cattle
FDA's 14th Emergency Response to New World Screwworm
The U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) on August 27, 2026, for Bimeda Animal Health Ltd.'s over-the-counter injectable drug 'Bimectin (ivermectin)' to prevent myiasis caused by New World screwworm (Cochliomyia hominivorax) in cattle. The EUA is limited to administration within 24 hours of birth, at castration, or at the time of wound occurrence. This is the FDA's 14th EUA issued since the U.S. Department of Health and Human Services (HHS) declared an emergency on August 18, 2025, aimed at reducing biological risks to North American livestock and food supply chains.
Label Expansion, Not Approval
Bimectin is a marketed injectable antiparasitic with the brand name Bimectin and generic name ivermectin, targeting glutamate-gated chloride channels (GluCl) in parasites to induce neuromuscular paralysis. While the FDA has already approved the product for treating and controlling various internal and external parasites in cattle and swine, the New World screwworm prevention indication is an EUA applicable only during the emergency period, not a full approval or based on Phase 1-3 clinical trials. The FDA's decision is based on reasonable likelihood of effectiveness and benefit-risk balance, not definitive proof of efficacy, and should be distinguished from regular label approvals.
Ivomec Monopoly Eased, Multi-Layer Defense Strengthened
Bimectin is a generic version of Boehringer Ingelheim's original 'Ivomec (ivermectin)' and received EUA for the same cattle prevention use on February 5, 2026. Competing options include Zoetis (ZTS)'s 'Dectomax-CA1 (doramectin)', which received conditional approval from the FDA on September 30, 2025, for prevention, treatment, and 21-day reinfestation prevention in cattle. Merck & Co. (MRK)'s 'Exzolt Cattle-CA1 (fluralaner)' also received conditional approval on December 4, 2025. Multiple manufacturers with different active ingredients reduce the risk of supply shortages leading to control failures.
Market Implications and Food Safety Constraints
The global animal parasiticides market was valued at USD 12.96 billion in 2025, and this action represents an expansion of generic access in the large animal pharmaceutical market. Bimectin is available without a prescription but has a 35-day slaughter withdrawal period and cannot be used in dairy cows or calves raised for beef. Therefore, its commercial value lies more in expanding farmers' preventive options and strengthening supply chain resilience than in simple sales growth. On-farm implementation requires concurrent record-keeping, slaughter scheduling, and residue management. The EUA remains valid until the HHS emergency declaration is lifted or the FDA revokes it, so long-term revenue sustainability must be evaluated separately from regular approvals.
With the global animal parasiticides market reaching USD 12.96 billion in 2025, Bimeda's marketed generic Bimectin has secured an EUA, easing Boehringer Ingelheim's Ivomec-dominated supply structure. In the short term, cattle farmers gain an additional source of ivermectin for the same target, but the 35-day slaughter withdrawal period and restrictions on use in dairy cows and beef calves may influence adoption speed. Mid- to long-term competition will unfold between EUA-stage Bimectin and Ivomec and conditionally approved products such as Zoetis (ZTS)'s Dectomax-CA1 and Merck & Co. (MRK)'s Exzolt Cattle-CA1. Bimeda has gained an emergency use revenue opportunity, but the EUA could end if the emergency declaration is lifted, making regular approval conversion and on-farm efficacy and resistance management data key value drivers for the company.